New drug combo aims to shrink ovarian tumors before surgery
NCT ID NCT07322094
First seen Jan 09, 2026 · Last updated Jun 13, 2026 · Updated 21 times
Summary
This study tests a new drug called TORL-1-23 given with standard chemotherapy before surgery for women with advanced ovarian cancer. About 60 participants with stage III or IV disease will receive the combination to see if it is safe and helps shrink tumors more effectively. The goal is to improve cancer control and delay the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.